Plus Therapeutics to Announce Third Quarter 2020 Financial Results and Host Conference Call on October 22, 2020

Rhea-AI Summary

Plus Therapeutics, Inc. (Nasdaq: PSTV) will release its third quarter 2020 financial results on October 22, 2020, after market close. A conference call will follow at 5:00 p.m. ET for management to discuss these results and provide corporate updates. The call will include a live webcast and can be accessed through their official IR page. Plus Therapeutics focuses on developing nanoliposome-encapsulated radionuclides targeted at rare cancers, aiming to enhance patient treatment through innovative drug delivery methods.

Positive

• Scheduled financial results announcement for Q3 2020 on October 22, signaling transparency and engagement with investors.

Negative

• None.

AUSTIN, Texas, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced that the company will report 2020 third quarter financial results on Thursday, October 22, 2020, after market close. Subsequently, Plus Therapeutics’ management team will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the financial results and provide a corporate update.

A live webcast will be available at ir.plustherapeutics.com/events   

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

Conference dial-in:	877-402-3914
International dial-in:	631-865-5294
Conference ID:	2108916
Conference Call Name:	Plus Therapeutics Third Quarter 2020 Financial Results Conference Call

Following the live call, a replay will be available on the Company’s website under the ‘Investors Relations’ section. The webcast will be available on the Company’s website for 90 days following the live call.

About Plus Therapeutics, Inc.

Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company’s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at plustherapeutics.com and respect-trials.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about: the Company’s potential to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers; the Company’s potential to develop drug candidates currently in its product pipeline; and the Company’s potential to develop additional drugs outside of its current pipeline. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including but not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA’s accelerated regulatory pathways; and the risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor Contact
Peter Vozzo
Westwicke/ICR
(443) 377-4767
Peter.Vozzo@westwicke.com

Media Contact
Terri Clevenger
Westwicke/ICR
(203) 856-4326
Terri.Clevenger@westwicke.com

FAQ

When will Plus Therapeutics report its Q3 2020 financial results?

Plus Therapeutics will report its Q3 2020 financial results on October 22, 2020, after market close.

What is the conference call date for Plus Therapeutics' Q3 2020 results?

The conference call will be held on October 22, 2020, at 5:00 p.m. Eastern Time.

How can I access the webcast for Plus Therapeutics' financial results?

The webcast for Plus Therapeutics' financial results can be accessed on their Investor Relations website.

What is Plus Therapeutics' focus regarding drug development?

Plus Therapeutics focuses on developing nanoliposome-encapsulated radionuclides aimed at treating rare cancers.